Tracey Gous1, Lewis Couchman, Jignesh P Patel, Chitongo Paradzai, Roopen Arya, Robert J Flanagan. 1. *Toxicology Unit, Department of Clinical Biochemistry, King's College Hospital NHS Foundation Trust; †Institute of Pharmaceutical Science, King's College London; and ‡King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom.
Abstract
BACKGROUND: Direct oral anticoagulants (DOACs) are prescribed for systemic anticoagulation. Fixed doses are recommended, but dose individualization may be warranted. Functional coagulation assays may be available, but their use requires knowledge of the drug taken. To provide alternative methodology for guiding dosage, we have developed and validated a liquid chromatography-mass spectrometric assay for apixaban, dabigatran, edoxaban, and rivaroxaban at the concentrations attained during therapy. METHODS: Samples, calibrators, and internal quality controls (100 μL) were mixed with internal standard solution (50 μg/L both dabigatran-13C6 and rivaroxaban-13C6 in acetonitrile) and, after centrifugation (16,400g, 4 minutes), supernatant (100 μL) was injected onto a Cyclone-C18-P-XL TurboFlow column. Analytes were focused onto an Accucore PhenylHexyl (2.1 × 100 mm, 2.6 μm) analytical column and eluted using a methanol + acetonitrile (1 + 1):aqueous ammonium acetate (10 mmol/L) gradient. Data were acquired using high-resolution mass spectrometry in full-scan mode (100-2000 m/z) with data-dependent fragmentation to confirm peak identity. Calibration was linear (1-500 μg/L all analytes). RESULTS: Total analysis time was 6 minutes. Intra-assay imprecision (% RSD) at 1 μg/L was 2.6%, 4.2%, 17.3%, and 9.5% for apixaban, dabigatran, edoxaban, and rivaroxaban, respectively. Mean recovery was 96%-101%. No signal suppression or enhancement was observed. Apixaban, dabigatran, and rivaroxaban were stable over 3 freeze-thaw cycles, after storage at room temperature, and at 2-8°C for up to 2 weeks. Edoxaban was stable over 3 freeze-thaw cycles but showed a mean deterioration of 16% if stored at 2-8°C (2 weeks) and of 18% and 70% (1 day and 2 weeks, respectively) at room temperature. CONCLUSIONS: The method is suitable for high-throughput therapeutic drug monitoring of DOACs. The acquisition of full scan data allows for the retrospective identification of metabolites. The method can be used to identify a particular DOAC if information on the drug taken is lacking.
BACKGROUND: Direct oral anticoagulants (DOACs) are prescribed for systemic anticoagulation. Fixed doses are recommended, but dose individualization may be warranted. Functional coagulation assays may be available, but their use requires knowledge of the drug taken. To provide alternative methodology for guiding dosage, we have developed and validated a liquid chromatography-mass spectrometric assay for apixaban, dabigatran, edoxaban, and rivaroxaban at the concentrations attained during therapy. METHODS: Samples, calibrators, and internal quality controls (100 μL) were mixed with internal standard solution (50 μg/L both dabigatran-13C6 and rivaroxaban-13C6 in acetonitrile) and, after centrifugation (16,400g, 4 minutes), supernatant (100 μL) was injected onto a Cyclone-C18-P-XL TurboFlow column. Analytes were focused onto an Accucore PhenylHexyl (2.1 × 100 mm, 2.6 μm) analytical column and eluted using a methanol + acetonitrile (1 + 1):aqueous ammonium acetate (10 mmol/L) gradient. Data were acquired using high-resolution mass spectrometry in full-scan mode (100-2000 m/z) with data-dependent fragmentation to confirm peak identity. Calibration was linear (1-500 μg/L all analytes). RESULTS: Total analysis time was 6 minutes. Intra-assay imprecision (% RSD) at 1 μg/L was 2.6%, 4.2%, 17.3%, and 9.5% for apixaban, dabigatran, edoxaban, and rivaroxaban, respectively. Mean recovery was 96%-101%. No signal suppression or enhancement was observed. Apixaban, dabigatran, and rivaroxaban were stable over 3 freeze-thaw cycles, after storage at room temperature, and at 2-8°C for up to 2 weeks. Edoxaban was stable over 3 freeze-thaw cycles but showed a mean deterioration of 16% if stored at 2-8°C (2 weeks) and of 18% and 70% (1 day and 2 weeks, respectively) at room temperature. CONCLUSIONS: The method is suitable for high-throughput therapeutic drug monitoring of DOACs. The acquisition of full scan data allows for the retrospective identification of metabolites. The method can be used to identify a particular DOAC if information on the drug taken is lacking.
Authors: Sudha Jayaraman; Jonathan H DeAntonio; Stefan W Leichtle; Jinfeng Han; Loren Liebrecht; Daniel Contaifer; Caroline Young; Christopher Chou; Julia Staschen; David Doan; Naren Gajenthra Kumar; Luke Wolfe; Tammy Nguyen; Gregory Chenault; Rahul J Anand; Jonathan D Bennett; Paula Ferrada; Stephanie Goldberg; Levi D Procter; Edgar B Rodas; Alan P Rossi; James F Whelan; Ventaka Ramana Feeser; Michael J Vitto; Beth Broering; Sarah Hobgood; Martin Mangino; Michel Aboutanos; Lorin Bachmann; Dayanjan S Wijesinghe Journal: J Trauma Acute Care Surg Date: 2020-04 Impact factor: 3.697
Authors: Joachim Kuhn; Tatjana Gripp; Tobias Flieder; Marcus Dittrich; Doris Hendig; Jessica Busse; Cornelius Knabbe; Ingvild Birschmann Journal: PLoS One Date: 2015-12-23 Impact factor: 3.240
Authors: Priscilla Bento Matos Derogis; Livia Rentas Sanches; Valdir Fernandes de Aranda; Marjorie Paris Colombini; Cristóvão Luis Pitangueira Mangueira; Marcelo Katz; Adriana Caschera Leme Faulhaber; Claudio Ernesto Albers Mendes; Carlos Eduardo Dos Santos Ferreira; Carolina Nunes França; João Carlos de Campos Guerra Journal: PLoS One Date: 2017-02-07 Impact factor: 3.240
Authors: Yvonne M C Henskens; Anouk J W Gulpen; René van Oerle; Rick Wetzels; Paul Verhezen; Henri Spronk; Simon Schalla; Harry J Crijns; Hugo Ten Cate; Arina Ten Cate-Hoek Journal: Thromb J Date: 2018-02-01
Authors: Sarah J Barsam; Jignesh P Patel; Lara N Roberts; Venu Kavarthapu; Raj K Patel; Bruce Green; Roopen Arya Journal: Res Pract Thromb Haemost Date: 2017-10-09